Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Diagnostic Hybrids, a developer and manufacturer of diagnostic and analytical products, and Case Western Reserve University have signed an exclusive worldwide licensing agreement granting Diagnostic Hybrids rights to a novel yeast-based virus cloning technology invented by human immunodeficiency virus researcher Eric Arts, associate professor of medicine in the division of infectious diseases, department of medicine at Case Western Reserve School of Medicine.
Subscribe to our email newsletter
The technology provides a platform of diagnostic tests used by physicians and researchers to monitor the success of anti-HIV treatment by determining drug resistance and disease strength of the virus. The technology can also be used for academic research to better understand this virus and to develop better vaccines.
In June 2008, Diagnostic Hybrids and Case Western Reserve were recipients of a $5 million grant from the Ohio third frontier biomedical research and commercialization program to accelerate the commercial development of a suite of diagnostic products using the yeast vector technology, including products and services related to HIV, hepatitis and influenza.
David Scholl, president and CEO of Diagnostic Hybrids, said: This licensing agreement, our most recent success in combining our effort to win support from the prestigious third frontier program, and the unusually high skill, collaborative talent, and overall commercial leadership on this project will prove pivotal to our translating the science into commercial opportunity for Diagnostic Hybrids and jobs in Ohio.